Compare Cytokinetics Inc (CYTK) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Hormel Foods Corp — how do they compare? Cytokinetics Inc trades at $62.73 (market cap $8.62B), while Hormel Foods Corp trades at $19.21 (market cap $10.69B). The key difference: Hormel Foods Corp is the larger of the two by market cap, and Hormel Foods Corp pays a 6.02% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Hormel Foods Corp for 99 Days on average.
| CYTK | HRL | |
|---|---|---|
Market Cap | $8.62B | $10.69B |
Volume | 2,594,626 | 10,041,387 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $26.50 |
52-Week Low | $54.76 | $19.42 |
Typical Hold Time | 19 Days | 99 Days |
Enterprise Value | $8.72B | $12.67B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Hormel Foods (HRL) trades at $19.55, down 1.66% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, while recent quarterly earnings have consistently beaten expectations. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, though cash flow trends show volatility with 2025 net cash flow negative $71M.
Outlook remains cautious with analyst consensus at Hold (57%) and $24.25 price target suggesting 24% upside. Key risks include declining profit margins, high payout ratios, and integration challenges from recent acquisition. The 60-year dividend streak provides stability but raises sustainability concerns amid shrinking raises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
